Basilea Pharmaceutica will finally be able to bring its antibiotic ceftobiprole to the US market, around 15 years after the drug was first turned down by the FDA.
A recent Biomedical Research & Bio-Products AG phase 2 study showed that its TSST-1 vaccine is safe and effective against Staphylococcal-induced Toxic Shock Syndrome (
Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down – thanks to a new phase 3 clinical trial.<
The FDA has approved Roche’s MRSA test, a technology that could give healthcare providers the ability to detect infections faster than traditional culture-based tests.